Repligen (RGEN) Stock: Buy, Sell, or Hold?
RGEN - Repligen Corp
$178.71
-1.30 (-0.72%)
âŧ
5d:
-2.96%
30d:
-3.15%
90d:
+35.43%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Oct 27, 2026
3d
Get Alerted When RGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: RGEN is fairly priced but lacks strong directional signals. At 3.2% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: RGEN is fairly priced but lacks strong directional signals. At 3.2% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$131.30
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$81.52
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RGEN is currently trading at $178.71, which is considered fair relative to its 30-day fair value range of $171.86 to $187.58. The stock's valuation (Forward PE: 66.3) is in line with its historical norms (60.4). At these levels, the market is pricing in 3.2% annual earnings growth.
Technical Outlook: Technically, RGEN is in a strong uptrend. Immediate support is located at $164.21, while resistance sits at $186.00.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $199.70 (+11.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RGEN is in a strong uptrend. Immediate support is located at $164.21, while resistance sits at $186.00.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $199.70 (+11.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$171.86 -
$187.58
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.3%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (44/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($199.70)
- BULLISH: Expecting earnings turnaround to 3.2% growth with 11.9% revenue growth
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$171.86 -
$187.58
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$164.21
Resistance Level
$186.00
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
66.26
Wall Street Target
$199.70
(+11.7%)
Revenue Growth (YoY)
11.9%
Earnings Growth (YoY)
-65.9%
Profit Margin
5.3%
Valuation Premium vs History
+3.2% premium
PE vs Historical
66.3 vs 60.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.2%
(market-implied from PE analysis)
1-Year Target
$184.43
(+3%)
2-Year Target
$190.33
(+7%)
3-Year Target
$196.42
(+10%)
3-Yr Target (if PE normalizes)
(PE: 66â60)
PE COMPRESSION
$179.04
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 66.3, Growth: 31.2%)
$403.75
(+126%)
Base:
(SPY PE: 19.9, Growth: 31.2%)
$121.01
(-32%)
Bear:
(PE: 16.9, Growth: 31.2%)
$102.86
(-42%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (67x PE), but valuation improves significantly next year (66x PE) as earnings recover.
Forward PE: 67.11 | Forward EPS (Implied): $2.66
Bull Case
$215.79
(+21%)
Analyst growth 15.0%, PE expands to 70.5
Base Case
$178.71
(0%)
Market implied 0.0%, PE stable at 67.1
Bear Case
$136.71
(-24%)
Severe decline -15.0%, PE contracts to 60.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 23, 2026 1:53 AM ET
Data refreshes hourly during market hours. Next update: 2:53 AM
Data refreshes hourly during market hours. Next update: 2:53 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
STRONG BUY
34 analysts |
$479 | 32 SELL |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$83 | 37 SELL |
|
WST
West Pharmaceutical ServâĻ |
STRONG BUY
17 analysts |
$413 | 41 HOLD |
|
STVN
Stevanato Group SpA |
BUY
14 analysts |
$24 | 63 BUY |
|
NVST
Envista Holdings Corp |
BUY
15 analysts |
$29 | 68 BUY |
